Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Infant, Newborn, Diseases
Description
Diseases of newborn infants present at birth (congenital) or developing within the first month of birth. It does not include hereditary diseases not manifesting at birth or within the first 30 days of life nor does it include inborn errors of metabolism. Both HEREDITARY DISEASES and METABOLISM, INBORN ERRORS are available as general concepts. MeSH
Hierarchy View
Subtype Terms (32)
Anemia, Neonatal
5 drugs (1 approved, 4 experimental)
Asphyxia Neonatorum
3 approved drugs
Birth Injuries
2 drugs (1 approved, 1 experimental)
Colic
39 drugs (13 approved, 26 experimental)
Congenital Bone Marrow Failure Syndromes
10 drugs (9 approved, 1 experimental)
Congenital Hyperinsulinism
16 drugs (13 approved, 3 experimental)
Cystic Fibrosis
309 drugs (156 approved, 153 experimental)
Epilepsy, Benign Neonatal
1 approved drug
Erythroblastosis, Fetal
4 drugs (3 approved, 1 experimental)
Hernia, Umbilical
8 drugs (6 approved, 2 experimental)
Hyperbilirubinemia, Neonatal
10 drugs (5 approved, 5 experimental)
Hyperostosis, Cortical, Congenital
Ichthyosis
15 drugs (6 approved, 9 experimental)
Infant, Premature, Diseases
89 drugs (62 approved, 27 experimental)
Meconium Aspiration Syndrome
7 drugs (2 approved, 5 experimental)
Neonatal Abstinence Syndrome
15 drugs (8 approved, 7 experimental)
Neonatal Sepsis
39 drugs (24 approved, 15 experimental)
Nystagmus, Congenital
1 experimental drug
Ophthalmia Neonatorum
3 drugs (1 approved, 2 experimental)
Persistent Fetal Circulation Syndrome
10 drugs (9 approved, 1 experimental)
Severe Combined Immunodeficiency
39 drugs (25 approved, 14 experimental)
Thrombocytopenia, Neonatal Alloimmune
1 experimental drug
Toxoplasmosis, Congenital
3 drugs (2 approved, 1 experimental)
Vitamin K Deficiency Bleeding
1 approved drug
Wolman Disease
14 drugs (11 approved, 3 experimental)
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (10)
Phase 2 Indicated Drugs (1)
Other Experimental Indicated Drugs (3)
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (55)
Bill and Melinda Gates Foundation
Case Western Reserve University
Centers for Disease Control and Prevention (CDC)
Katholieke Universiteit Leuven
Moorgreen Hospital, Southampton
National Center for Research Resources (NCRR)
National Heart, Lung, and Blood Institute (NHLBI)
National Institute of Child Health and Human Development (NICHD)
National Institutes of Health (NIH)
Organization Involved with Phase 2 Indications (3)
Organization Involved with Other Experimental Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
